Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct;39(5):913-922.
doi: 10.5114/ada.2022.120884. Epub 2022 Nov 9.

Assessment of the post-SARS-CoV-2 vaccination response depending on the epidemiological status, demographic parameters and levels of selected cytokines in medical personnel

Zbigniew Bartuzi  1 , Tomasz Rosada  1 , Natalia Ukleja-Sokołowska  1 , Katarzyna Napiórkowska-Baran  1 , Kinga Lis  1 , Magdalena Żbikowska-Gotz  1 , Wojciech Kowalczyk  1 , Ewa Szynkiewicz  1 , Ewa Alska  1 , Łukasz Cała  1
Affiliations

Assessment of the post-SARS-CoV-2 vaccination response depending on the epidemiological status, demographic parameters and levels of selected cytokines in medical personnel

Zbigniew Bartuzi et al. Postepy Dermatol Alergol. 2022 Oct.

Abstract

Introduction: SARS-CoV-2 is responsible for causing the COVID-19 disease, which affected 174 million people worldwide. After vaccines were launched, the focus was on their effectiveness and the degree of their safety.

Aim: The authors try to find factors that may affect the response to vaccination.

Material and methods: The study was conducted in 47 adults (39 women and 8 men; age: 47.3 ±11.2). Participants were vaccinated with two doses of the Comirnaty mRNA vaccine. Each patient had a medical history taken and the concentration of specific sIgG antibodies against S1 protein and SARS-CoV-2 N protein, as well as of selected cytokines (IL-8, TGF-β, IFN-γ) was determined before and 3 weeks after the first and second dose of the vaccine.

Results: There were 18 convalescents among the respondents. A statistically significant increase in the concentration of specific sIgG S1 in subsequent determinations was observed. Higher levels of sIgG S1 were found after the first dose of the vaccine in COVID-19 convalescents. There was no statistically significant influence of age, body mass index and sex on the increase in the concentration of antibodies and the concentration of the determined cytokines. It was shown that the higher the initial TGF-β concentration, the greater the increase in sIgG S1 after administration of the vaccine.

Conclusions: Vaccination did not increase the levels of IL-8, IFN-β and TGF-γ. A higher concentration of serum TGF-β before vaccination correlated with the higher concentration of sIgG S1 antibodies after the first dose of the vaccine.

Keywords: COVID 19; IgG S1; SARS-CoV 2; interferon-γ; interleukin-8; transforming growth factor-β; vaccination.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Parallel coordinates plot for each patient’s IgG SARS S1 before vaccination and after first and second dose
Figure 2
Figure 2
Influence of positive COVID diagnosis before vaccination on the rise of antibodies after first and second vaccination
Figure 3
Figure 3
Baseline level of TGF-β and its influence on the concentration of IgG SARS S1 after first dose of vaccination
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol 2021; 19: 141-54. - PMC - PubMed
    1. Kirtipal N, Bharadwaj S, Kang SG. From SARS to SARS-CoV-2, insights on structure, pathogenicity and immunity aspects of pandemic human coronaviruses. Infect Genet Evol 2020; 85: 104502. - PMC - PubMed
    1. V’kovski P, Kratzel A, Steiner S, et al. . Coronavirus biology and replication: implications for SARS-CoV-2. Nat Rev Microbiol 2021; 19: 155-70. - PMC - PubMed
    1. Wang MY, Zhao R, Gao LJ, et al. . SARS-CoV-2: structure, biology, and structure-based therapeutics development. Front Cell Infect Microbiol 2020; 10: 587269. - PMC - PubMed
    1. Campos DMO, Fulco UL, de Oliveira CBS, Oliveira JIN. SARS-CoV-2 virus infection: targets and antiviral pharmacological strategies. J Evid Based Med 2020; 13: 255-60. - PMC - PubMed